Andrew R. Macintyre, Ph.D. Joins ABL, Inc. as Director of Immunobiology

ROCKVILLE, Md.--(BUSINESS WIRE)--ABL, Inc. (ABL), a biomedical contract research and manufacturing organization serving the biotechnology and pharmaceutical industries, today announced the hiring of Dr. Andrew Macintyre as Director of Immunobiology. In this role, Dr. Macintyre will lead ABL's newly expanded clinical operations team, supporting our clients with assay development through to sample testing.

Dr. Macintyre brings over 20 years of expertise in immunological research and 15 years of industry experience to ABL, having worked in a wide variety of international environments developing, validating and executing assays for pharmacokinetic, immunogenicity and biomarker assessments.

He most recently served as Director, Research and Development at Pacific Biomarkers where he led strategic planning initiatives for the evaluation and validation of new assays and platforms, provided oversight of laboratory testing operations, and guided laboratory compliance efforts to meet quality goals and regulatory standards for research and development activities. He worked as a resource for clients, presenting new innovations through both educational and business venues. His leadership at Pacific Biomarkers, along with prior positions at SNBL USA, Cardinal Health, Charles River Laboratories, and the UK National Health Service, has provided Dr. Macintyre a wealth of experience ensuring preclinical and clinical programs meet critical endpoints through assay method design, development, validation and management of testing operations.

Dr. Macintyre trained in Oncology and Clinical Laboratory Medicine, specializing in Immunology and Hematology, receiving his PhD in Veterinary Pathology from the University of Liverpool and a M.Sc. in Medical Immunology from Manchester Metropolitan University.

On the addition of Dr. Macintyre, Dr. Thomas VanCott, President and CEO of ABL, commented, "I am very pleased to welcome Dr. Macintyre to the ABL team. Andy's career has been focused on delivering scientific and operational value to clients, and his insights will add significantly to ABL's ability to provide practical, actionable solutions to meet our clients' clinical goals in an ever-changing global regulatory environment. "

On his new position, Dr. Macintyre stated, "ABL is at a very exciting point in terms of expansion of facilities and capabilities; it is an opportune time to join the company. I look forward to working with the talented scientific team at ABL to advance its innovative work and contributing to the growth and expansion of the core immunobiology laboratory."

Dr. Macintyre will direct the operational and strategic growth of ABL's U.S. clinical testing laboratory, dedicated to conducting clinical testing protocols in support of Ph I – III trials. Focusing on immunological analyses, ABL's clinical testing laboratory provides clients with a broad portfolio of capabilities – from ELISpot to flow cytometry to multiplexing technologies – designed to quantify the impact of candidate products on the innate and humoral immune systems.

About ABL

Advanced BioScience Laboratories, Inc. (ABL) is a biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. With facilities located in Rockville, MD, USA and Lyon, France, ABL has extensive experience working with diverse organizations, including government agencies, academic laboratories and commercial bio/pharmaceutical companies. Notable services include basic research, product design, process and assay development, preclinical studies, clinical immunogenicity testing, and Phase I/II cGMP biologics manufacturing. Since 2001 ABL has been a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.

Contacts

ABL, Inc.
Andrew A. Arrage
Vice President, Business Development
301-816-5209
[email protected]

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.